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https://doi.org/10.1016/j.celrep.2020.108105SUMMARYCirculating tumor cells (CTCs) are shed from solid cancers in the form of single or clustered cells, and the
latter display an extraordinary ability to initiate metastasis. Yet, the biological phenomena that trigger the
shedding of CTC clusters from a primary cancerous lesion are poorly understood. Here, when dynamically
labeling breast cancer cells along cancer progression, we observe that the majority of CTC clusters are un-
dergoing hypoxia, while single CTCs are largely normoxic. Strikingly, we find that vascular endothelial growth
factor (VEGF) targeting leads to primary tumor shrinkage, but it increases intra-tumor hypoxia, resulting in a
higher CTC cluster shedding rate andmetastasis formation. Conversely, pro-angiogenic treatment increases
primary tumor size, yet it dramatically suppresses the formation of CTC clusters and metastasis. Thus, intra-
tumor hypoxia leads to the formation of clustered CTCs with high metastatic ability, and a pro-angiogenic
therapy suppresses metastasis formation through prevention of CTC cluster generation.INTRODUCTION
Circulating tumor cells (CTCs) are considered to be metastatic
precursors in several cancer types, including breast cancer, but
the mechanisms that lead to their generation from a solid tumor
mass are poorly understood (Alix-Panabie`res and Pantel,
2014). CTCs are shed as single cells, as multicellular aggre-
gates (CTC clusters), or in association with immune or stromal
cells (Aceto et al., 2015; Duda et al., 2010; Gkountela et al.,
2019; Szczerba et al., 2019). While cluster formation generally
leads to an increased metastatic ability (Aceto et al., 2014,
2015; Cheung and Ewald, 2016; Cheung et al., 2016; Gkountela
et al., 2019; Szczerba et al., 2019), whether CTC clusters are
released from a cancerous lesion in a passive or active manner
is unknown. Several factors have been linked to the ability of
cancer cells to metastasize, such as cell-autonomous upregu-
lation of metastasis-promoting genes (Bos et al., 2009; Kang
et al., 2003; Massague´ and Obenauf, 2016; Minn et al., 2005)
or genes involved in the formation of a pre-metastatic niche
(Esposito et al., 2018; Peinado et al., 2017), interaction with
the immune system (Coffelt et al., 2015; Szczerba et al.,Ce
This is an open access article under the CC BY-N2019), or microenvironmental signals (Gilkes et al., 2014; Quail
and Joyce, 2013).
Particularly in the context of the microenvironment, intra-tu-
mor hypoxia and deregulated angiogenesis have emerged as
key factors involved in cancer progression (Hanahan and Wein-
berg, 2011; Ho¨ckel and Vaupel, 2001; Jain, 2005). In contrast to
healthy tissues, cancer cells are able to survive in hypoxic con-
ditions and take advantage of the hypoxic microenvironment in
multiple ways. For instance, hypoxia has been linked to chemo-
therapy and radiotherapy resistance of cancer cells (Comerford
et al., 2002; Gray et al., 1953; Jain, 2005; Samanta et al., 2014) as
well as increased metastasis formation (Rankin and Giaccia,
2016), and high levels of HIF1a expression—the master hypoxia
regulator (Semenza, 1998)—correlate with a poor prognosis in
patients with cancer (Baba et al., 2010). Anti-angiogenic thera-
pies, typically targeting the vascular endothelial growth factor
(VEGF) pathway (Vasudev and Reynolds, 2014), have been orig-
inally developed to reduce intra-tumor vasculature and conse-
quently starve the tumor from its nutrients (Folkman, 1971). A
growing body of evidence has also highlighted a vascular
normalization signal for anti-angiogenic therapies as a functionll Reports 32, 108105, September 8, 2020 ª 2020 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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OPEN ACCESSof tumor type as well as therapy dosage and schedule (Goel
et al., 2011; Jain, 2013), unexpectedly resulting in improved
blood flow, density, and mural cell coverage of blood vessels
(Carmeliet and Jain, 2011). However, in breast cancer, anti-
angiogenic treatments have failed to consistently prolong sur-
vival of patients, and paradoxically, intra-tumor hypoxia remains
a hallmark of breast cancer biology (Gligorov et al., 2014; Jayson
et al., 2016; Lang et al., 2013; Miller et al., 2007; Robert et al.,
2011).
Several studies have suggested that hypoxic cancer cells are
endowed with increased metastatic ability. Through HIF1a, hyp-
oxia has been linked to metabolic changes during tumor pro-
gression, such as the transcription of genes encoding glucose
transporters and glycolytic enzymes, favoring theWarburg effect
(Mucaj et al., 2012; Semenza, 2010). Hypoxia has also been
linked to phenotypic changes involved in cancer biology, such
as an epithelial-to-mesenchymal transition (Lundgren et al.,
2009). In a tumor, hypoxia is generally expected to be confined
to the core and within regions that are poorly vascularized. How-
ever, this is an apparent paradox in the context of metastasis
biology because metastatic cancer cells need to have access
to functional blood vessels to achieve dissemination.We thought
of tackling this controversy by directly addressing the role of
hypoxia in spontaneousmetastasis models in vivo and in relation
to CTC generation and metastasis.
RESULTS
Hypoxic Areas Retain Functional Blood Vessels
We first sought to dynamically trace spontaneous hypoxic
events by generating an activity reporter vector for HIF1a
(HIF1a reporter) expressing enhanced yellow fluorescent protein
(eYFP) under the control of hypoxia-response element (HRE) re-
peats (Figure 1A). We transduced the HIF1a reporter in human
breast CTC-derived cells (BR16) directly obtained from a liquid
biopsy (Gkountela et al., 2019), in human metastatic breast can-
cer cells (MDA-MB-231 lung metastatic variant, referred to as
‘‘LM2’’) (Minn et al., 2005), and in mouse breast cancer cells ob-
tained from spontaneously arising primary tumors (4T1). We
confirmed elevated eYFP levels both upon treatment with the HI-
F1a-stabilizer deferoxamine (DFO) (Figure S1A) and as a conse-Figure 1. Dynamic Labeling and Assessment of Intra-Tumor Hypoxia
(A) Schematic representation of the HIF1a reporter.
(B) Schematic of the experimental design.
(C) Representative pictures of breast tumors displaying a hypoxic core (left) or s
(D) The plot shows the percentage of core versus scattered hypoxic areas in LM
(E) Schematic of the experimental design.
(F) The plot shows the percentage of CD31-positive (+) cells within the normoxic a
reporter (eYFP; n = 4), pimonidazole staining (Pimo; n = 4), or the lack of both (n
(G) The plot shows the distribution in percentage of functional vessels within th
reporter (eYFP; n = 4) or Pimo staining (n = 4).
(H) Representative images of NSG-BR16-HIF1a reporter tumors stained for hum
CD31, and Dex (right). White triangles highlight Dex-positive vessels.
(I) The plot shows the density in percentage of functional blood vessels in normoxic
tumors.
(J) Representative images of NSG-BR16-HIF1a reporter tumors stained for hCK,
intravasating eYFP(+) single CTC (middle), and intravasated eYFP() single C
For all panels, the error bars represent the SEM. See also Figures S1 and S2.quence to incubation in hypoxic conditions (0.1%O2), compared
to control cells and to cells exposed to 5% O2 (Figures S1B and
S1C). Of note, when transferring the cells back to normoxic (20%
O2) conditions, we could confirm the dynamic and reversible na-
ture of our approach (Figures S1B and S1C). These results were
also validated at the level of HIF1a protein expression (Figures
S1D–S1F). As further controls, we confirmed that HIF1a knock-
down completely abolished the ability of transduced cells to ex-
press eYFP and did not result in compensatory HIF2a expression
(Figures S1G and S1H), and stimulation with reactive oxygen
species (ROS) inducers or tricarboxylic acid cycle (TCA) metab-
olites failed to activate eYFP expression (Figure S1I), confirming
the specificity of the reporter system.
We then injected reporter cancer cells into the mammary fat
pad of immunocompromised (NOD scid gamma; NSG) mice
and monitored spontaneous tumor development, aiming to visu-
alize the emergence of hypoxic regions and determine their
localization (i.e., either as hypoxic core or as scattered hypoxic
areas) (Figure 1B). The expression of the HIF1a reporter did
not alter tumor growth kinetics (Figure S2A), nor did it influence
the overall course of the metastatic disease compared to control
cells (Figure S2B). Primary tumors were then immunostained for
mCherry (tumor cells), eYFP (HIF1a-expressing tumor cells), pi-
monidazole (gold standard to define hypoxic areas) (Varia et al.,
1998), as well as CD31 (endothelial cells) to highlight intra-tumor
hypoxic regions and the distribution of blood vessels throughout
the tumor tissue. We observed a bimodal hypoxia distribution in
tumors, either restricted within a central core or scattered
throughout the tumor volume, yet in all cases characterized by
distinct hypoxic regions with defined borders (Figures 1C, 1D,
and S2C; Video S1). The percent of eYFP-positive or pimonida-
zole-positive cells within primary tumors varied between models
and in individual mice, ranging from amean of 5.6% to amean of
64.1% (Figures S2D–S2F), with eYFP-positive cells co-localizing
with pimonidazole regions in 31.1% to 54.9% of the cases (Fig-
ure S2G). As expected, the extent of the co-localization between
eYFP and pimonidazole is influenced by the nature of the two
methods: while eYFP is detectable only several hours after the
establishment of hypoxia and labels cells that experienced pro-
longed hypoxic conditions to assemble eYFP (Figures S1A and
S1B), pimonidazole uptake occurs rapidly in all areas that arecattered hypoxic areas (right).
2, BR16, and 4T1 tumor models.
nd the hypoxic tumor areas of NSG-BR16-HIF1a reporter mice, defined HIF1a
ormoxia; n = 5).
e hypoxic tumor areas of NSG-BR16-HIF1a reporter mice, defined by HIF1a
an cytokeratin (hCK), eYFP, CD31, and Dextran (Dex) (left) or with hCK, Pimo,
(n = 7), eYFP (n = 4), or Pimo-stained (n = 4) areas of NSG-BR16-HIF1a reporter
eYFP, CD31, and Dex and showing intravasating eYFP(+) CTC cluster (left),
TC (right). White triangles highlight the intravasation sites.
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Figure 2. Dynamic Labeling of Hypoxic CTCs and Assessment of Their Metastatic Potential
(A) Representative pictures of CTC clusters (top) and single CTCs (bottom) from NSG-LM2-HIF1a reporter mice, positive (+) or negative () for eYFP expression.
(B) The plot shows themean percentage of eYFP(+) single CTCs (n = 3) and CTC clusters (n = 3) fromNSG-LM2-HIF1a reporter mice. Error bars represent SEM;
p value by two-tailed unpaired Student’s t test is shown.
(C) Schematic of the experimental design.
(D) Kaplan-Meier survival analysis of NSGmice injected with eYFP(+) (n = 4) or eYFP() (n = 3) CTC clusters or single CTCs. p value by log-rank test is shown.
See also Figures S3 and S4.
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pound (Varia et al., 1998).
Next, we asked whether hypoxic regions of the tumor are
perfused by functional blood vessels (Figure 1E). To this end,
we intravenously injected dextran in tumor-bearing mice and as-
sessed its presence within the vasculature of both hypoxic and
normoxic regions. First, we found that CD31-positive cells (i.e.,
endothelial cells) are present throughout the tumor (Figure S2H)
and distributed in both hypoxic and normoxic regions, with a
higher presence in normoxic tumor regions (Figures 1F and
S2I). Of note, the vast majority of blood vessels found in either
eYFP- or pimonidazole-positive tumor areas also resulted posi-
tive for dextran, suggesting their functionality (Figures 1G, 1H,
S2J, and S2K), while the density of functional blood vessels
was higher in normoxic tumor regions compared to hypoxic
ones, as expected (Figures 1I and S2L). Lastly, intravasation
events were observed for eYFP-positive cancer cells in
dextran-positive vessels (Figure 1J). Altogether, these results
suggest that intra-tumor hypoxia occurs in spatially defined
areas that are characterized by the presence of functional blood
vessels, albeit at a lower density compared to normoxic tumor
regions, highlighting a possible intravasation route for hypoxic
cancer cells to the circulation.
CTC Clusters Originate from Hypoxic Tumor Regions
We next investigated the hypoxic status of live CTCs, spontane-
ously originating from tumor-bearing mice. To this end, wemade
use of the HIF1a reporter through eYFP detection, and not pimo-
nidazole, for two main reasons. First, pimonidazole staining re-
quires fixation, which would not allow us to perform functional
assays with the isolated CTCs. Second, differently from pimoni-
dazole, eYFP labels cells that experienced hypoxia for several
hours, presumably starting at the level of the primary tumor given
the short half-life of CTCs in circulation (Aceto et al., 2014), allow-4 Cell Reports 32, 108105, September 8, 2020ing us to focus on consolidated hypoxic events leading to sus-
tained HIF1a activity. We first established that the number and
composition of spontaneously generated CTCs were not altered
by the expression of our HIF1a reporter system (Figure S3A).
Strikingly however, we found that while the majority of single
CTCs are normoxic (i.e., eYFP negative), CTC clusters are largely
hypoxic in all three tested models (Figures 2A, 2B, S3B, and
S3C), with the majority of the cells in each cluster being eYFP
positive (Figures S3D–S3G). Of note, despite the fact that in
the slow-growing BR16 model only a mean of 5.6% of primary
tumor cells was eYFP positive (Figure S2E), we found a mean
of 80.6% of CTC clusters to be positive for eYFP (Figure S3C),
strongly suggesting their origin from hypoxic tumor areas and
arguing against stochastic CTC intravasation dynamics.
To assess whether hypoxic CTC clusters are endowed with a
greater metastatic potential compared to their normoxic
counterparts, we first injected LM2-HIF1a reporter cells in the
mammary fat pad of NSG mice, and upon tumor development,
spontaneously generated single CTCs and CTC clusters were
individually isolated, micromanipulated, and separated into
‘‘eYFP positive’’ or ‘‘eYFP negative’’ (Figure 2C). We found a
higher ratio of Ki67-positive cells among hypoxic CTCs (both sin-
gle and clustered) (Figures S3H–S3J). While hypoxic CTC clus-
ters were generally found to contain a higher number of cells (a
mean of 5.3 cells per hypoxic CTC cluster versus a mean of
2.82 cells per normoxic CTC cluster; p < 0.001) (Figure S3K),
we intravenously injected a total of 100 cells per recipient tu-
mor-free mouse for all groups for direct assessment of their met-
astatic potential, without disrupting the multicellular structure of
CTC clusters (Figure 2C). Mice injected with hypoxic CTC clus-
ters developed metastasis earlier and survived for a shorter
time than those injected with normoxic CTC clusters, high-
lighting the higher metastasis-seeding ability of hypoxic CTC
clusters (Figure 2D). Hypoxic single CTCs were not endowed
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Figure 3. Hypoxic CTC Clusters Express a Gene Signature That Is Associated with a Poor Prognosis in Breast Cancer Patients
(A) Schematic of the experimental design.
(B) Representative pictures of CTC clusters fromNSG-LM2-GFP/Luc, NSG-BR16 xenografts, and BR61 patient stained with HypoxiaRed and processed for RNA
sequencing. The apparent cut in the HypoxiaRed-positive CTC cluster is due to the positioning of the CTC cluster relative to the pinhole.
(C) Heatmap showing differentially expressed genes between hypoxic (n = 14) and normoxic (n = 17) CTC clusters from NSG-LM2, NSG-BR16, and BR61 (FDR <
0.25).
(D) Density plot showing the distribution of CTC clusters and single CTCs from theGSE109761 dataset (n = 13 breast cancer patients) according to the expression
of the hypoxic cluster signature. p value by one-tailed Student t test is shown.
(E) Overall survival rate of stage I breast cancer patients expressing in their primary tumor high (quantile 4, Q4) or low (quantile 1, Q1) levels of genes upregulated in
hypoxic CTC clusters (top). The number of patients that progressed at each time point is shown (bottom). p value by log-rank test is shown.
(legend continued on next page)
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OPEN ACCESSwith a greater metastatic ability compared to their normoxic
counterparts, suggesting that hypoxia without clustering is not
sufficient to increase themetastatic potential of cancer cells (Fig-
ure 2D). These findings are in line with previous publications
highlighting the higher metastatic ability of CTC clusters
compared to single CTCs (Aceto et al., 2014; Gkountela et al.,
2019; Szczerba et al., 2019), given that the majority of clustered
CTCs are found to be hypoxic. We also realized that virtually all
CTC-white blood cell (WBC) clusters (Szczerba et al., 2019) from
this model are hypoxic, and as expected, their direct metastatic
ability exceeds that of hypoxic CTC clusters that were not asso-
ciated with WBCs (Figures S3L–S3O). We then repeated the
same experiment with the BR16-HIF1a model and confirmed
the elevated metastatic ability of clustered hypoxic CTCs
compared to their normoxic or single-cell counterparts (Figures
S3P and S3Q).
Identification of a Hypoxic CTC Cluster Gene Signature
Wenext sought to interrogate the gene expression profile of hyp-
oxic CTC clusters. To this end, we isolated live CTCs from a
breast cancer patient (BR61) and two breast cancer xenografts
(BR16 and LM2) and labeled them with HypoxiaRed, a cell-
permeable dye that directly tags hypoxic cells based on their ni-
troreductase activity (Lizama-Manibusan et al., 2016), allowing
gene expression profile comparison of hypoxic versus normoxic
CTC clusters (Figure 3A). In contrast to eYFP, HypoxiaRed al-
lowed us to label hypoxic CTCs independently of the exposure
time to low oxygen concentrations, enabling the processing of
live cells from freshly isolated blood samples. In control experi-
ments, we demonstrate that HypoxiaRed positivity increases in
hypoxic conditions (0.1% O2) (Figure S4A), and it correlates
with eYFP expression in HIF1a reporter cells and CTCs upon
hypoxia induction (Figures S4B–S4E). In the same experiments,
we also demonstrate that the vast majority of eYFP-positive
CTCs (97%) from tumor-bearing mice stain positive for Hypo-
xiaRed and pimonidazole, extending the validity of our approach
(Figure S4E), and we detect a correlation between HypoxiaRed
or eYFP intensity and CTC cluster size, as expected (Figure S4F).
Lastly, to ensure that our procedure does not artificially create
hypoxic cells, we intravenously injected normoxic LM2 cells in
tumor-free mice, then processed blood samples at different
time points (0, 15, and 30 min; consistent with the circulation
half-life of CTC clusters) after injection and compared Hypo-
xiaRed or eYFP positivity to control cells treated with DFO
(Figure S4G). Importantly, we only found HypoxiaRed or eYFP
positivity in control cells that were treated with DFO (Figure S4H),
confirming that our procedure does not artificially create hypoxic
cells.
Following CTC isolation and HypoxiaRed staining, in line with
our previous findings, we observed a higher HypoxiaRed
positivity in CTC clusters compared to in single CTCs (Figures
S4I–S4K). We then individually micromanipulated a total of 28
HypoxiaRed-positive versus 33 HypoxiaRed-negative CTC clus-
ters from xenografts and a patient sample and processed them(F) Distant metastasis-free survival rate of breast cancer patients expressing in th
CTC clusters (top). The number of patients that progressed at each time point is
See also Figure S5 and Tables S1, S2, and S3.
6 Cell Reports 32, 108105, September 8, 2020for RNA sequencing (Figure 3B). Since hypoxic CTC clusters
generally contain more cells than their normoxic counterparts
(Figure S4L), typically resulting in a higher number of genes de-
tected in single-cell RNA sequencing experiments (data not
shown), we only considered 2- and 3-cell clusters for the RNA
sequencing analysis in order to avoid technical biases. Differen-
tial expression analysis highlighted that hypoxic CTC clusters (as
defined by HypoxiaRed positivity as well as expression of HIF1a
and VEGFA; Figure S5A) differ in the expression of 32 genes
(false discovery rate [FDR] < 0.25) compared to their normoxic
counterparts (as defined by HypoxiaRed negativity and the
absence of expression of HIF1a and VEGFA; Figure S5A), of
which 25 upregulated and 7 downregulated (Figure 3C; Tables
S1 and S2). In contrast, no changes were observed between
hypoxic and normoxic clusters in terms of total number of de-
tected genes or in the expression of genes related to cell cycle
or epithelial-to-mesenchymal transition (Figures S5B–S5D).
Among upregulated genes, in addition to HIF1a and VEGFA,
we note GDF15, CCNG2, and P4HA1, previously associated
with hypoxia (Fujimura et al., 2013; Lakhal et al., 2009; Xiong
et al., 2018), as well as genes that were not previously linked to
hypoxic conditions. To validate these findings, we evaluated
the expression of our 25-gene signature found upregulated in
hypoxic CTC clusters (‘‘hypoxic cluster signature’’) in single
and clustered CTCs (n = 88) from 13 breast cancer patients
and found that our hypoxic cluster signature is significantly upre-
gulated in CTC clusters (p = 0.003) (Figure 3D). We next tested
whether our signature could predict the clinical outcome of
breast cancer patients with early disease and no clinical evi-
dence of metastasis (i.e., stage I, all subtypes from The Cancer
Genome Atlas [TCGA] dataset) (Table S3). Strikingly, we found
that low expression levels of the hypoxic cluster signature in
the primary tumor correlate with 100% 10-yr survival rate of pa-
tients, while high expression levels predict a poor prognosis, as
indicated by lower survival rates (p = 0.037) (Figure 3E). We
observe that this predictive value is superior to previous hypox-
ia-related signatures (mostly obtained from in vitro data and bulk
analyses) (Buffa et al., 2010; Elvidge et al., 2006; Ragnum et al.,
2015; Winter et al., 2007) (Figure S5E). Lastly, in the advanced
disease setting, we also find that high expression of the hypoxic
cluster signature predicts a shorter metastasis-free survival (p =
0.0024) in a cohort of 1,746 breast cancer patients (Figure 3F).
Thus, hypoxia triggers the expression of a defined gene set in
CTC clusters in vivo, highly predictive of a poor prognosis in
breast cancer patients.
Proteomic Profiling of Hypoxic Cancer Cells
We next aimed at characterizing the protein expression profile of
hypoxic and normoxic cancer cells directly isolated from the pri-
mary tumor of mice bymeans of an unbiased tandemmass tags-
labeling strategy followed by mass spectrometry. We aimed to
identify proteins that could mediate hypoxia-driven clustering
in vivo. In particular, live primary tumor cells expressing the
HIF1a reporter were digested and dissociated into single cellseir primary tumor high (Q4) or low (Q1) levels of genes upregulated in hypoxic
shown (bottom). p value by log-rank test is shown.
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trometry analysis (Figure 4A). This strategy was chosen—as
opposed to Hypoxia Red labeling—to allow protein production
and assembly upon hypoxia induction, along with the expression
of eYFP. Among 10,574 detected peptides, corresponding to
2,541 unique human proteins (Table S4), we found that 176 pro-
teins are enriched in eYFP-positive tumor cells, while 498 are
downregulated, compared to eYFP-negative tumor cells (q %
0.1; Figure 4B). Gene Ontology (GO) analysis of enriched pro-
teins revealed upregulation of proteins involved in cell adhesion,
cadherin, and protein binding (Figure 4C), consistent with a
model whereby hypoxia leads to increased cancer cell clus-
tering. In contrast, GO analysis of proteins upregulated in
eYFP-negative tumor cells revealed enrichment in different mo-
lecular functions, including DNA and RNA binding (Figure 4D).
Further, we isolated single and clustered CTCs, either positive
or negative for eYFP, to investigate specific changes at the pro-
tein level occurring in circulation in addition to the primary tumor
site (Figure S5F). Among 24,482 peptides (corresponding to
3,033 unique human proteins; Table S5) detected in hypoxic
and normoxic CTCs, we found that 418 proteins are enriched
in eYFP-positive CTCs (single and clustered) and 988 are down-
regulated, compared to eYFP-negative CTCs (q % 0.1; Fig-
ure S5G). GO analysis of the proteins upregulated in hypoxic
CTCs revealed an enrichment in cell adhesion, cadherin, and
protein binding (Figure S5H), strongly mirroring the pattern of
hypoxic cells within the primary tumor, as expected, given the
short half-life of CTCs in circulation (Aceto et al., 2014). Detailed
analysis highlighted the involvement of several players including
NDRG1, previously associated with hypoxia and cell-cell junc-
tion stability (Lachat et al., 2002) (Figure 4E). We further validated
NDRG1 expression in pimonidazole-positive tumor areas of
mice through immunohistochemistry staining (Figures 4F and
S5I) and confirmed its elevated expression at the protein level
upon hypoxia induction in vitro (Figure 4G). Next, we reasoned
that given its upregulation as a consequence of hypoxia and its
involvement in cell-cell junctions of epithelial cells, a lack of
NDRG1 should not affect intra-tumor hypoxia levels, yet should
negatively impact CTC cluster formation upon hypoxia induc-Figure 4. Hypoxic Tumor Cells Upregulate Cell-Cell Adhesion Proteins
(A) Schematic of the experimental design.
(B) Volcano plot showing all the proteins detected with mass spectrometry analy
(C) Gene ontology (GO) analysis of molecular function pathways upregulated in h
(D) GO analysis of molecular function pathways upregulated in normoxic tumor c
(E) Heatmap showing the expression levels of the top 20 upregulated proteins bel
value.
(F) Representative pictures showing Pimo and human NDRG1 staining from LM2
(G) Representative western blot shows NDRG1 protein in LM2-mCherry/Luc cell
(H) Representative western blot shows hNDRG1 protein in LM2-mCherry/Luc cell
(sh-1 and sh-2).
(I) The plot shows themean tumor volume of NSGmice injected with LM2-mCherr
unpaired Student’s t test are shown.
(J) The plot shows themean percentage of CD31(+) cells within the primary tumo
(n = 4). p values by two-tailed unpaired Student’s t test are shown.
(K) The plots show themean percentage of Pimo(+) cells colocalizing with primar
knockdown (n = 4). p values by two-tailed unpaired Student’s t test are shown.
(L) Pie charts displaying the mean percentage of single CTCs and CTC clusters in
For all panels, the number of independent biological replicates (n) is shown, and
8 Cell Reports 32, 108105, September 8, 2020tion. Consistently, we found that NDRG1 knockdown in vivo
does not affect primary tumor size, abundance of CD31-positive
cells, or intra-tumor hypoxia (Figures 4H–4K), but it decreases
spontaneous CTC cluster generation (Figure 4L).
HIF1a Is Not Required for CTC Cluster Formation or
Metastasis
We next tested whether HIF1a itself, beyond its role as an es-
tablished hypoxia-associated transcription factor (Semenza,
1998), is also directly involved in the mechanisms that promote
CTC cluster generation and their higher ability to metastasize.
To this end, we generated inducible HIF1a knockdown in
LM2 and BR16 cells, resulting in HIF1a suppression upon treat-
ment with Doxycycline (Dox) (Figures 5A and 5B). We then in-
jected these cells in the mammary fat pad of NSG mice and
monitored primary tumor growth, CTC generation, and sponta-
neous metastasis formation upon Dox treatment. While Dox
treatment successfully enabled the expression of HIF1a short
hairpin RNAs (shRNAs) throughout the experiment in vivo (Fig-
ure 5C), we did not observe any differences in primary tumor
size, CTC composition, metastasis formation, or overall survival
between HIF1a knockdown and control mice (Figures 5D–5H).
Pimonidazole staining also highlighted that HIF1a knockdown
did not decrease the overall levels of intra-tumor hypoxia;
rather, it increased them (Figure 5I). Given that VEGFA is a
direct target of HIF1a transcriptional activity (Hicklin and Ellis,
2005), we then asked whether VEGFA expression was
decreased as a consequence of HIF1a knockdown. Interest-
ingly, we found that VEGFA mRNA levels were not altered
upon HIF1a suppression (Figures 5J and 5K), confirming that
in our cells, HIF1a is not the sole transcriptional activator of
VEGFA (Page`s and Pouysse´gur, 2005). Along these lines, we
also conclude that hypoxic cancer cells express high levels of
HIF1a, VEGF, and NDRG1, among others, and while NDRG1
has been previously shown to be a target of several transcrip-
tion factors including HIF1a (Said et al., 2017), its expression in
hypoxic cells appears to be not exclusively controlled by
HIF1a, given that HIF1a knockdown does not phenocopy the
effects observed through NDRG1 depletion.In Vivo
sis (q% 0.1).
ypoxic tumor cells and ranked by adjusted p value.
ells and ranked by adjusted p value.
onging to the GO terms enriched in hypoxic tumor cells. Ranking is based on q
-HIF1a reporter tumor.
s induced with either DFO or hypoxia (0.1% O2).
s expressing a control shRNA (control), NDRG1 shRNA-1, or NDRG1 shRNA-2
y/Luc expressing a control shRNA,NDRG1 sh-1, or sh-2. p values by two-tailed
r of LM2-mCherry/Lucmice expressing a control shRNA orNDRG1 knockdown
y tumor cells of LM2-mCherry/Lucmice expressing a control shRNA orNDRG1
LM2-mCherry/Luc mice expressing a control shRNA or NDRG1 knockdown.
the error bars represent SEM. See also Figure S5 and Tables S4 and S5.
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OPEN ACCESSVEGFA Targeting Reduces Primary Tumor Size but
Increases CTC Clusters and Metastasis
Given that VEGFA levels remain unaltered upon HIF1a suppres-
sion, we next asked whether the expression of VEGFA itself in
cancer cells—as part of our hypoxic CTC clusters signature
but also as a master angiogenesis regulator (Forsythe et al.,
1996; Harper and Bates, 2008) and target of anti-angiogenic
therapies (Vasudev and Reynolds, 2014)—could play a role in
promoting CTC cluster generation and metastasis. To this end,
we used Dox-inducible vectors expressing GFP along with
shRNAs targeting the human or mouse VEGFA transcript and
transduced them in LM2 or 4T1 cells, respectively. Upon Dox
stimulation, we confirmed both the knockdown of VEGFA using
two independent shRNAs as well as the expression of GFP (Fig-
ure S6A). We then injected LM2- and 4T1-shVEGFA cells in the
mammary fat pad of NSG mice and monitored tumor progres-
sion. As expected, tumors expressing VEGFA shRNAs retained
shRNA expression in vivo, grew slower and presented a
decreased percent of CD31-positive cells relative to the total tu-
mor area (i.e., fewer blood vessels), along with a higher positivity
for pimonidazole (Figures 6A–6C and S6B–S6E). Strikingly, how-
ever, despite the slower growth rate of VEGFA knockdown tu-
mors, we observed a remarkable increase in overall CTC counts
and a shift toward CTC cluster production compared to control
tumors of the same size (1,000 mm3 for LM2 and 700 mm3 for
4T1) in both models (from 11.4% to 24.5%–25.6% of CTC clus-
ters in the LM2 model and from 25.8% to 32%–40.6% of CTC
clusters in the 4T1 model) (Figures 6D–6F and S6F–S6H). The
increased CTC cluster ratio and overall CTC counts also led to
increased metastasis formation in animals bearing a VEGFA
knockdown tumor (Figures 6G, 6H, S6I, and S6J). Of note,
VEGFA knockdown did not influence the expression of HIF1a
or HIF2a (Figure S6K). Given that VEGFA knockdown increases
CTC cluster shedding and metastasis, we then asked whether
treatment of mice with bevacizumab—an FDA-approved mono-
clonal antibody widely used for VEGFA targeting in cancer as
well as other indications (Ferrara et al., 2004)—would phenocopy
these results. We chose a high dose of bevacizumab to mimicFigure 5. Knockdown of HIF1a Does Not Affect CTC Cluster or Metast
(A) Representative western blot shows the human HIF1a protein in LM2-GFP/Luc
hHIF1a shRNA-1, or hHIF1a shRNA-2 (sh-1 and sh-2).
(B) Representative pictures showing LM2-GFP/Luc cells upon knockdown.
(C) Representative pictures showing tumor (top) and metastatic lungs (bottom) o
(D) The plots show the mean tumor volume of NSG mice injected with LM2-GFP
knockdown. p values by two-tailed unpaired Student’s t test are shown.
(E) Plots showing the log10 of total CTC counts per ml of blood obtained from NS
shRNA or HIF1a knockdown. p values by two-way ANOVA are shown.
(F) The plots show the percentage of CTC clusters from NSG-LM2-GFP/Luc (le
knockdown. p values by two-tailed unpaired Student’s t test are shown.
(G) The plot shows the metastatic index of NSG-LM2-GFP/Luc (left) or NSG-BR
values by two-tailed unpaired Student’s t test are shown.
(H) Overall survival rates of NSG-LM2-GFP/Luc (left) or NSG-BR16-GFP/Luc (righ
log-rank test is shown.
(I) The plot shows themean percentage of Pimo(+) cells colocalizing with the prim
expressing a control shRNA control (n = 5 and n = 23) or HIF1a knockdown (sh
Student’s t test are shown.
(J) Plot showing HIF1a mRNA expression levels upon HIF1a knockdown (n = 2).
(K) Plot showing hVEGFA mRNA expression levels upon HIF1a knockdown (n =
For all panels, the number of independent biological replicates (n) is shown, and
10 Cell Reports 32, 108105, September 8, 2020our complete VEGFA suppression through shRNA expression,
corresponding to 25 mg/kg (von Baumgarten et al., 2011). In
full accordance with our VEGFA shRNA results, treatment with
25 mg/kg bevacizumab reduced primary tumor growth rate,
accompanied by a decreased number of CD31-positive cells
and increased pimonidazole positivity (Figures 6I–6K). Despite
the smaller size of the primary tumor, bevacizumab-treated
mice displayed a clear increase in overall CTC counts and CTC
cluster production compared to larger control tumors
(1,000 mm3 for controls and 489 mm3 for bevacizumab-treated
mice), resulting in increased metastatic burden (Figures 6L–
6P). Together, our results suggest that VEGFA targeting leads
to tumor shrinkage, slower growth rate, and reduced vasculari-
zation, but it also promotes intra-tumor hypoxia, leading to
increased CTC cluster shedding and accelerated metastasis
formation.
A Pro-Angiogenic Therapy Suppresses Spontaneous
Metastasis Formation
Based on our VEGFA targeting results, we then sought to
address whether the opposite scenario (i.e., an increased tumor
vascularization) could serve as a strategy to prevent the genera-
tion of CTC clusters and delay metastasis formation. We first
tested our hypothesis in two fast-growing breast cancer models:
LM2 and 4T1 injected in NSG mice. As a first step, we trans-
duced both cell lines with a bicistronic construct expressing
the mouse form of VEGFA (mVEGFA164) along with the truncated
form of mouse CD8a transmembrane protein (mCD8aTr) (Ozawa
et al., 2004), and then we selected clones with similar levels of
mVEGFA164 expression, prospectively inferred through anti-
mCD8aTr live staining (Figures S7A and S7B). We then injected
two LM2- mVEGFA164-IRES-mCD8aTr clones (LM2-mVIC) and
a control LM2-mCD8aTr clone (LM2-mC) in the mammary fat
pad of NSG mice, simultaneously treated with either EphrinB2
Fc chimera protein—previously shown to activate EphB4
signaling and to ensure normal and functional angiogenesis
along with elevated VEGFA levels (Groppa et al., 2018; Ozawa
et al., 2004)—or Fc fragments as controls (Figure 7A). Whileasis Formation
(top) and BR16-GFP/Luc (bottom) cells expressing a control shRNA (control),
f NSG-LM2-GFP/Luc mice expressing HIF1a shRNAs.
/Luc (left) or BR16-GFP/Luc (right) and expressing a control shRNA or HIF1a
G-LM2-GFP/Luc (left) or NSG-BR16-GFP/Luc (right) mice expressing a control
ft) or NSG-BR16-GFP/Luc (right) mice expressing a control shRNA or HIF1a
16-GFP/Luc (right) mice expressing a control shRNA or HIF1a knockdown. p
t) mice expressing a control shRNA or HIF1a knockdown. p value by two-sided
ary tumor cells of NSG-LM2-GFP/Luc (left) or NSG-BR16-GFP/Luc (right) mice
-1, n = 8 and n = 6; sh-2, n = 11 and n = 21). p values by two-tailed unpaired
p values by two-tailed unpaired Student’s t test are shown.
2).
the error bars represent SEM.
BA C D
E
Single CTCs CTC clusters
11.40% 25.6% 24.58%
Control hVEGFA sh-1 hVEGFA sh-2
F
1.5x1010
0.5x1010
Control hVEGFA sh-1 hVEGFA sh-2
Lu
ng
s
Tu
m
or
 v
ol
um
e 
(m
m3
)
1 2 3 4 5 6 7 8
0
500
1000
1500
Time (weeks)
Control
hVEGFA sh-1
hVEGFA sh-2
Single CTCs CTC clusters
Control (n=5)
hVEGFA sh-1 (n=7)
hVEGFA sh-2 (n=7)
0
1
2
3
Fo
ld
 c
ha
ng
e
Con
trol
hVE
GFA
 
sh-1
hVE
GFA
 
sh-2
0.0
0.2
0.4
0.6
0.8
1.0
%
 C
D3
1 
(+)
ce
lls
Con
trol
hVE
GFA
 
sh-1
hVE
GFA
 
sh-2
0
10
20
30
P=0.022
P=0.003
n = 5 n = 7
P=0.019
P=0.027
P=0.003
P=0.039
n = 7
p
=0.007
p
=0.003
%
Pi
m
o 
(+)
 ce
lls
co
lo
c.
 to
 tu
m
or
 a
re
a
Con
trol
hVE
GFA
 
sh-1
hVE
GFA
 
sh-2
0
20
40
60
80
100
P=0.048
P=0.009
G H
I J
Bevacizumab
Control
P
<0.0001
Single 
CTCs
CTC 
clusters
Bevacizumab (n=3)
Control (n=4)
P=0.002
Control Bevacizumab
Con
trol
Beva
cizu
mab
0.0
0.5
1.0
1.5
2.0
P=0.008
n = 4 n = 4
23.6% 31.3%
1.5x1010
0.5x1010
Control Bevacizumab
Lu
ng
s
Single CTCs CTC clusters
Bevacizumab (n=4)
Control (n=4)
1 2 3 4 5 6
0
500
1000
1500
Time (weeks)
Tu
m
or
 V
ol
um
e 
(m
m3
)
Con
trol
Beva
cizu
mab
0
5
10
15
20
%
CD
31
 (+
) c
e
lls
P=0.0263
Con
trol
Beva
cizu
mab
0
20
40
60
80
%
 P
im
o 
(+)
 ce
lls 
co
lo
c.
 tu
m
or
 a
re
a
P=0.0130
Control (n=7)
hVEGFA sh-1 
(n=9)
hVEGFA  sh-2 
(n=12)
Single CTCs CTC clusters
0
1
2
3
4
5
6
Lo
g1
0 
CT
Cs
/m
l
P=0.011
P=0.033
P=0.011
P=0.033
K L
M N O P
Single 
CTCs
CTC 
clusters
0
1
2
3
4
5
6
Lo
g1
0 
CT
Cs
/m
l
P=0.008 P=0.008
0.0
0.5
1.0
1.5
2.0
Fo
ld
 C
ha
ng
e
Long Treatment
M
et
as
ta
tic
 in
de
x 
(P
h/s
)
M
et
as
ta
tic
 in
de
x 
(P
h/s
)
Figure 6. VEGFA Targeting Increases CTC Cluster Shedding and Metastasis Formation
(A) The plot shows the mean tumor volume of NSG mice injected with LM2-mCherry/Luc cells and expressing a control shRNA (control) or hVEGFA shRNAs
(hVEGFA sh-1 and sh-2) (n = 7). p values by two-tailed paired Student’s t test are shown.
(B) The plot shows themean percentage of CD31-positive (+) cells within the primary tumor of NSG-LM2mice expressing a control or VEGFA knockdown (n = 6 in
control and sh-2; n = 4 in sh-1). p values by two-tailed unpaired Student’s t test are shown.
(C) The plot shows themean percentage of Pimo(+) cells colocalizing with primary tumor cells of NSG-LM2mice expressing a control or VEGFA knockdown (n =
3). p values by two-tailed unpaired Student’s t test are shown.
(D) Plot showing the log10 of total CTC counts per ml of blood in NSG-LM2 mice expressing a control or VEGFA knockdown. p values by two-way ANOVA are
shown.
(E) Pie charts displaying the mean percentage of single CTCs and CTC clusters in NSG-LM2 mice expressing a control or VEGFA knockdown.
(F) The plot shows the mean fold change of CTC ratios in NSG-LM2 mice expressing a control or VEGFA knockdown. p values by two-way ANOVA are shown.
(G) The plot shows the metastatic index of NSG-LM2 control (n = 7), NSG-LM2-hVEGFA sh-1 (n = 9), and sh-2 (n = 8) mice. p values by two-tailed unpaired
Student’s t test are shown.
(H) Representative bioluminescence images of lungs from NSG-LM2 mice expressing a control or VEGFA knockdown.
(legend continued on next page)
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OPEN ACCESSEphrinB2 ormVIC expression alone did not dramatically alter pri-
mary tumor growth rate, the simultaneous expression of mVIC
and EphrinB2 treatment led to the formation of tumors character-
ized by a similar growth rate, yet able to reach the maximum al-
lowed size in our license (2,800mm3) without causing any sign of
distress in the tumor-bearing mice (Figure 7B). Primary tumor
analysis revealed that LM2-mVIC tumors treated with EphrinB2
retained mVIC expression throughout the in vivo assay and
also displayed increased CD31 positivity and decreased pimoni-
dazole reactivity (Figures S7C–S7E), consistent with reduced
intra-tumor hypoxia. Most importantly, despite having signifi-
cantly larger tumors, mice with LM2-mVIC tumors treated with
EphrinB2 generated fewer CTCs and displayed a reduced CTC
cluster ratio compared to control animals (Figures 7C, 7D, and
S7F), leading to a marked reduction in spontaneous metastasis
formation and longer overall survival (Figures 7E, 7F, and S7G).
As further confirmation in an independent model, we also
observed a higher tumor growth rate associated with a longer
overall survival in mice carrying a 4T1-mVIC tumor and treated
with EphrinB2 (Figures S7H–S7K). Lastly, we asked whether
these findings were reproducible in CTC-derived BR16 breast
cancer cells, inherently characterized by the ability to form
slow-growing tumors and displaying a higher number of func-
tional vessels and lower intra-tumor hypoxia compared to the
LM2 model (Figures 1G, S2F, and S2J). In this case, given the
above, we tested whether the administration of EphrinB2 alone
(i.e., withoutmVIC expression) would be sufficient to recapitulate
the effects observed in the LM2 and 4T1 models. Treatment of
BR16 xenografts with EphrinB2 led to the formation of signifi-
cantly larger tumors (Figure 7G) characterized by higher CD31
positivity and reduced reactivity to pimonidazole (Figures S7L
and S7M). Strikingly, EphrinB2-treated BR16 xenografts failed
to generate CTC clusters (20.4% of CTC clusters for controls
and 0% of CTC clusters for EphrinB2) and displayed overall
reduced CTC shedding (Figures 7H, 7I, and S7N), leading to
the suppression of spontaneous metastasis formation (Figures
7J and 7K). Of note, in all tested models, we find that Ephrin
type-B receptor 4 (EphB4)—the target receptor of EphrinB2—
is highly expressed in endothelial cells but not in cancer cells,
arguing that EphrinB2 acts at the level of the endothelium (Fig-
ures S7O and S7P). Lastly, we tested whether a treatment with
EphrinB2 could be beneficial in the advanced disease setting
(i.e., when metastases are already established). We reasoned
that even in a very late setting, a pro-angiogenic approach by
means of EphrinB2 treatment could improve the tumor vascula-(I) The plot shows the mean tumor volume of NSG mice injected with LM2-mChe
(n = 5). p values by two-tailed unpaired Student’s t test are shown.
(J) The plot shows the mean percentage of CD31(+) cells within the primary tum
two-tailed unpaired Student’s t test are shown.
(K) The plot shows the mean percentage of Pimo(+) cells colocalizing with prim
acizumab (n = 5). p values by two-tailed unpaired Student’s t test are shown.
(L) Plot showing the log10 of total CTC counts per ml of blood in NSG-LM2-mChe
shown.
(M) Pie charts displaying the mean percentage of single CTCs and CTC clusters
(N) The plot shows the mean fold change of CTC ratios in NSG-LM2 treated with
(O) The plot shows themetastatic index of NSG-LM2 treatedwith control (n = 4) or b
(P) Representative bioluminescence images of lungs from NSG-LM2 mice treate
For all panels, the number of independent biological replicates (n) is shown, and
12 Cell Reports 32, 108105, September 8, 2020ture at metastatic sites and increase the delivery of tumor-killing
drugs administered simultaneously (Stylianopoulos et al., 2018).
To this end, we injected LM2 breast cancer cells through the tail
vein of mice and waited for the development of growing lungme-
tastases, per se sufficient to cause the death of the animal within
a short period (i.e., without the need of further disease spread)
(Figure 7L). Then, we administered either paclitaxel or EphrinB2
alone or a combination of the two agents and measured overall
survival of treated mice. While EphrinB2 alone did not exert
any beneficial effect (as expected, given that no newmetastases
were needed to be formed prior to experiment termination), a
combination of EphrinB2 and paclitaxel outperformed all other
conditions, including paclitaxel itself, confirming the beneficial
effects of a pro-angiogenic therapy in combination with a tu-
mor-killing agent in advanced disease settings (Figures 7L and
7M).
DISCUSSION
Our study suggests that intra-tumor hypoxia is a main trigger of
the upregulation of cell-cell junction components and generation
of hypoxic CTC clusters, endowedwith a high proclivity to initiate
metastasis. We propose that a pro-angiogenic therapy through
treatment with EphrinB2may increase vascularization and tumor
growth rate, yet also suppress intra-tumor hypoxia and intrava-
sation of clustered CTCs, leading to a reduction in metastasis
formation.
A number of studies have linked intra-tumor hypoxia and
HIF1a expression to metastasis formation (Rankin and Giaccia,
2016), but the actual impact of hypoxia in CTC biology is poorly
understood. We find that hypoxic cancer cells present signifi-
cantly upregulated cell-cell junction components, a property
that promotes intravasation of clustered CTCs rather than indi-
vidual ones and logically supports that hypoxic cancer cells in
the bloodstream aremost often found in the form of CTC clusters
or CTC-WBC clusters. Surprisingly, we observe that hypoxic tu-
mor areas are not devoid of functional blood vessels, highlighting
possible accessibility routes for metastatic cells to the circula-
tory system. While this is important for explaining how hypoxic
tumor cells can reach the periphery, whether intravasation
events from hypoxic areas occur more frequently through veins
(low intravascular oxygen levels) or arteries (high intravascular
oxygen levels) remains to be defined. We use several methods
to assess the hypoxic status of cancer cells during tumor
progression, including direct staining with pimonidazole orrry/Luc cells and treated with isotype control (n = 4) or bevacizumab 25 mg/Kg
or of NSG-LM2 mice treated with control or bevacizumab (n = 4). p values by
ary tumor cells of NSG-LM2-mCherry/Luc mice treated with control or bev-
rry/Luc treated with control or bevacizumab. p values by two-way ANOVA are
in NSG-LM2-mCherry/Luc treated with control or bevacizumab.
control or bevacizumab. p values by two-way ANOVA are shown.
evacizumab (n = 2). p values by two-tailed unpaired Student’s t test are shown.
d with control or bevacizumab.
the error bars represent SEM. See also Figure S6.
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Figure 7. Pro-Angiogenic Therapy Reduces Intra-Tumor Hypoxia and Suppresses the Formation of CTC Clusters and Metastasis
(A) Schematic of the experimental design.
(B) The plot shows themean tumor volume of NSGmice injected with LM2-mCherry/Luc cells expressingmVIC (mVIC) or control CD8aTr (mC), treated with either
control FC fragments (FC) or EphrinB2 (EpB2). p values by two-tailed unpaired Student’s t test are shown.
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test are shown.
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(legend continued on next page)
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OPEN ACCESSHypoxiaRed, in addition to a stably integrated eYFP-based re-
porter system. A combination of these is needed, given that
each of these methods presents its own challenges, such as
eYFP half-life leading to its persistence for a period of time
upon hypoxia cessation, the need for fixation prior to pimonida-
zole staining limiting downstream molecular analysis, or the
inability of HypoxiaRed to be used directly in vivo.
Hypoxic CTC clusters are destined to retain their hypoxic sta-
tus at least until dissemination (i.e., the hypothesis that hypoxic
CTC clusters may rapidly reacquire a normoxic status in circula-
tion is highly unrealistic for several reasons). For instance, CTC
clusters are characterized by a short circulation half-life (i.e., a
fewminutes; Aceto et al., 2014), most likely due to rapid physical
entrapment in small capillary beds at distant sites. In this
context, their biology is governed by events that occurred at
the level of the primary tumor (e.g., the hypoxic microenviron-
ment) and that are reflected during circulation. Based on our ex-
periments aimed at assessing the metastatic potential of hypox-
ic and normoxic CTC clusters, features that characterize hypoxic
CTC clusters appear to be key for metastasis seeding indepen-
dently of the oxygen levels encountered in circulation or at the
target metastatic site, and both hypoxic and normoxic cancer
cells retain their original (hypoxic or normoxic) status while circu-
lating. Further, the circulatory system alternates venous and
arterial blood, where oxygen levels vary dramatically (Harrop,
1919). While CTCs are destined to collect in venous blood
soon after they exit the tumor, whether they also experience arte-
rial circulation mainly depends on the location of the extravasa-
tion site (e.g., upstream or downstream of the pulmonary circuit).
Thus, both circulation half-life and the extravasation site are key
parameters that influence a CTC’s oxygen accessibility, and cur-
rent data support a model whereby hypoxia (or normoxia) in
CTCs reflects the condition that cancer cells experienced at
the level of the primary tumor, just before intravasation.
VEGFA targeting is widely used in the clinical setting not only
for cancer treatment, but also in other indications (Ferrara
et al., 2007). Our experiments demonstrate that VEGFA suppres-
sion by means of shRNA expression or treatment with a high
dose of bevacizumab results in tumor shrinkage—as previously
shown in several models (Chiron et al., 2014; Gerber et al., 2000;
Li et al., 2014)—but at the expense of reducing vascularization,
leading to increased hypoxia. While these results are useful to
gain important insights into the consequences of intra-tumor
hypoxia for the metastatic process in breast cancer, it is impor-
tant to underline that a large body of literature has also high-
lighted a vascular normalization effect for anti-VEGFA therapies
as a function of therapy dosage and schedule (Jain, 2005, 2013),
possibly influenced by tumor-intrinsic characteristics such as
the extent and frequency of hypervascularized areas.(I) The plot shows mean fold change of CTC ratios in NSG-BR16-mCherry/Luc tre
test are shown.
(J) The plot shows the metastatic index of NSG-BR16-mCherry/Luc mice treated
are shown.
(K) Representative bioluminescence images of metastatic lungs from NSG-BR16
(L) Schematic of the experimental design.
(M) Overall survival rates of NSG-LM2-mVIC mice treated with paclitaxel, EpB2,
For all panels, the number of independent biological replicates (n) is shown, and
14 Cell Reports 32, 108105, September 8, 2020In our study, wemake use of treatment with EphrinB2 (alone or
in combination with VEGFA expression, depending on the
growth rate of individual models) to achieve increased and
normalized vascularization. EphrinB2 acts by binding and
activating its receptor on endothelial cells, EphB4, achieving a
regulation of intussusceptive angiogenesis and fine-tuning of
endothelial proliferation induced by VEGF signaling (Groppa
et al., 2018) and resulting into normal vessel formation and a
reduction of intra-tumor hypoxia. Several other strategies may
directly or indirectly lead to vascular normalization (Goel et al.,
2011). These might be particularly interesting in the context of
metastasis prevention, rather than for the effects that they exert
on tumor growth. While this notion might be useful for the treat-
ment of tumors that have not yet disseminated, we show that
treatment of post-dissemination breast cancer (i.e., correspond-
ing to stage IV disease) requires the co-administration of Eph-
rinB2 with a tumor-killing agent, such as chemotherapy. In this
context, Ephrin may not only prevent further metastasis-to-
metastasis cascading disseminations, but also improve
perfusion of the existing cancerous lesions, thus facilitating the
tumor-killing activity of the co-administered compound. Clinical
studies on well-defined patient populations will be key to
address this point in the future.
Altogether, our study provides key insights into the role of hyp-
oxia in CTC cluster generation. The next challengewill be to trans-
late these findings to the clinical setting, as the optimal strategy
might differ for individual patients as a function of their tumor sub-
type, organ location, andmolecular characteristics, as well as the
presence or absence of already-disseminated tumor cells with
the ability to survive at distant sites. We speculate that therapies
aimed at reducing intra-tumor hypoxia, alone or in combination
with anticancer agents, may provide a new opportunity to blunt
the metastatic spread of cancer in breast cancer patients.STAR+METHODS
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Human blood samples collection
Patient blood specimens were obtained at the University Hospital Basel through the study protocols (EKNZ BASEC 2016-00067 and
EK 321/10), approved by the local ethics committee (EKNZ, Ethics Committee northwest/central Switzerland). The patients involved
were characterized by having invasive breast cancer, high tumor load and progressive disease. In particular, breast cancer patient
BR61, female of age 63 at time of blood withdrawal, was characterized by having a ER-positive, PR-negative and HER2-negative
disease at primary tumor diagnosis, and later developed bone, lymph node, soft tissue, brain, adrenal gland and pancreatic metas-
tases at the time of CTC isolation. BR61 donated 7.5 –15ml blood in EDTA vacutainers at multiple time points during disease
progression, upon written informed consent.
Mouse blood samples collection
All mouse experiments were carried out in compliance with institutional and cantonal guidelines (approved mouse protocol #2781,
cantonal veterinary office of Basel-City). NOD/scid GAMMA (NSG) mice were purchased from Jackson Laboratory and kept in path-
ogen-free conditions specified by the University of Basel and cantonal veterinary office of Basel-City. Mouse blood was retrieved via
cardiac puncture of NSG female mice (age range 8-12 weeks), and up to 1 mL of blood was collected.
Cell lines
MDA-MB-231-LM2 (LM2) human triple negative breast cancer cell line was obtained from Dr. Joan Massague´, MSKCC, NY, USA.
CTC-derived BR16 cells were generated and cultured from the corresponding patient as previously described (Gkountela et al.,
2019). 4T1 murine breast cancer cells were purchased from ATCC (4T1 ATCC CRL-2539). HEK293T Phoenix packaging cells, Hu-
man umbilical cord endothelial cells (HUVEC) and Mouse aortic endothelial cells (MAEC) were kindly donated by Dr. Andrea Banfi,
University Hospital Basel, Switzerland.
METHOD DETAILS
Cell culture
LM2, 4T1, and HEK293T cells were grown in DMEM F-12 high glucose (GIBCO, 11330-057) supplemented with 10% heat-inacti-
vated FBS (GIBCO, 10500064) and 1% antimycotic/antibiotic (GIBCO, 15240-062) in a humidified incubator at 37 C with 20% O2
and 5% CO2. BR16 cells were grown as suspension cultures in RPMI medium (GIBCO, 52400-025) supplemented with 1X B27
(GIBCO, 17504-044), 1% antimycotic/antibiotic, 20 ng/ml human recombinant Fibroblast Growth Factor (FGF; Peprotech,
100-18B) and 20 ng/ml human recombinant Epidermal Growth Factor (EGF; Invitrogen, PHG0313) in a humidified incubator at
37 C with 5% O2 and 5% CO2, using ultra-low attachment plates (Sarstedt, 83.3920.500). HUVEC and MAEC were grown in
endothelial cell growth medium 2 (ready-to-use) (Promocell, C-22011) supplemented with 1% antimycotic/antibiotic. LM2, 4T1
and BR16 cells were stably transduced with lentiviral vectors expressing UBC_GFP-T2A-Firefly Luciferase (GFP/Luc) (System
Biosciences, BLIV200PA-1-SBI) or ready-to-use virus EF1a_Firefly Luciferase-T2A-mCherry (mCherry/Luc) (Biosettia, GlowCell-
15-10).
HIF1a activity reporter
The HIF1a activity reporter (HIF1a reporter) was purchased from Genecopoeia upon providing the exact nucleotide sequence. The
human hypoxia response element (HRE) of the human VEGFA gene (‘‘50 - CCACAGTGCATACGTGGGCTCCAACAGGTCCTCTT
30’’) (Harada et al., 2007) is followed by a CMV minimal promoter (CMVmp) (Shibata et al., 2000) and by an enhanced yellow fluo-
rescent protein (eYFP) sequencewithin a lentiviral vector. Transduced cells were selectedwith 5 mg/ml Puromycin (Invitrogen, ant-pr-
1) for 5 days (4T1) or 0.5 mg/ml for 5 days (LM2) or 15 days (BR16), respectively. Treatment with Deferoxamine (DFO; Sigma, D9533)
500 mM was used to induce the stabilization of HIF1a in LM2, 4T1 and BR16 cells, for 4, 8 and 15 hours, respectively. Alternatively,
HIF1a induction was achieved using the humidified hypoxia chamber (Biospherix, ProOx 110) at 0.1% O2. Anti-HIF1a (Novus,
NB100-449) antibodies were used to confirm HIF1a induction through western blot, with anti-GAPDH antibody (Cell Signaling,
2118S) as loading control.
Live imaging of HIF1a reporter
LM2, 4T1 and BR16 mCherry/Luc cells, expressing the HIF1a reporter, were seeded into coated (LM2 and 4T1) or uncoated (BR16)
imaging chambers (Ibidi, 80826 and 80821), respectively. Following treatment with DFO, Diethyl Fumarate (DF; Sigma, D95654),
Dimethyl Succinate (DS; Sigma, 73605), Rotenone (RT; Sigma, R8875) or Hydrogen peroxide (H2O2; Sigma, H1009), cells within
chambers were cultured under the humidified live imaging box of the microscope Leica DMi8, at 37C and 20% O2. For live imaging
experiments requiring hypoxia, cells within chambers were cultured at 5% O2 or 0.1% O2.Cell Reports 32, 108105, September 8, 2020 e2
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LM2 and BR16 cells were stably transduced with doxycycline (Dox)-inducible shRNAs, targeting the Open Reading Frame (ORF) of
human HIF1a (50 - AAAGATATGATTGTGTCTC - 30and 50 - TGCATCTCGAGACTTTTCT - 30), (Dharmacon, TRIPZ). LM2 and 4T1
cells were stably transduced with Dox-inducible shRNAs targeting ORF of human VEGFA (50-CAGGGTCTCGATTGGATGG - 30, 50 -
AGTAGCTGCGCTGATAGAC - 30), ormouseVegfa (50-ACCGCCTTGGCTTGTCACA - 30, 50 - ACCGCCTTGGCTTGTCACA - 30) (Dhar-
macon, SMART), respectively. The transduced cells were selected using 0.5 - 5 mg/ml puromycin and subsequently sorted, upon
treatment with 0.1 mg/ml doxycycline (Dox; Sigma, D9891) for 2 days, for the highest expression of the shRNA-coupled fluorophore
(TurboGFP or TurboRFP). hHIF1a knockdown was measured by western blot as described above or by qPCR using previously
described primers (Chen et al., 2014). Anti-HIF2a (Novus, NB100-122SS) antibodies were used to measure HIF2a protein level by
western blot. hVEGFA and mVegfa knockdown was measured by qPCR using previously described primers (Chen et al., 2014; Mu-
jagic et al., 2013). hGAPDH (forward primer: 50 - GAAGGTGAAGGTCGGAGTCAAC - 30, reverse primer: 50 - CAGAGTTAAAAG
CAGCCCTGGT - 30) or mGapdh (forward primer: 50 - AATGGTGAAGGTCGGTGTG - 30, and reverse primer: 50 -GTGGAGTCATACTG
GAACATGTAG - 30) were used as load controls. Treatment with DFO 500 mM was used to induce the stabilization of HIF1a in LM2,
4T1 and BR16 cells, for 4, 8 and 15 hours, respectively, upon 5 days of treatment with 0.1 mg/ml Dox.
mVEGFA164-tCD8a overexpression
mVEGFA164-mCD8aTr and mCD8aTr only were transduced in LM2 and 4T1 mCherry/Luc as previously described (Mujagic et al.,
2013). Clonal populations were derived from single cells, obtained through single-cell sorting with BD FACS ARIA in 96-well plates.
Successfully growing clones were expanded and analyzed for CD8aTr expression at the CytoFLEX (Beckman Coulter Life sciences,
V-B-R series) upon staining with anti-CD8aTr APC (Biolegend, 100712) or isotype control Rat IgG2a (Biolegend, 400511) as previ-
ously described (Misteli et al., 2010). Clones were further selected based on morphology and stable expression of CD8aTr over mul-
tiple in vitro culture passages.
EphB4 western blot analysis
HUVEC, LM2, BR16, MAEC and 4T1 cells were incubated in the presence of 1 mg/ml of recombinant mouse Ephrin-B2-hFC chimera
(R&D Biosystem, 496-EB-200) or ChromPure IgG hFC fragment (Jackson Immuno research, 009-000-008) for 3 hours and subse-
quently lysed. Anti-hEphB4 (R&D systems, AF3038-SP) and anti-mEphB4 (R&D systems, AF446-SP) antibodies were used to confirm
EphB4 induction through western blot, with anti-GAPDH antibody as loading control.
Mouse experiments
Orthotopic injection was performed between the second and third mammary gland of adult female mice (age range 8-12 weeks) with
either 1x106 LM2, 1x106 BR16 or 0.25x106 4T1 cells, expressing the fluorescent construct GFP/Luc or mCherry/Luc. Cells were inoc-
ulated in 50% Cultrex Path Clear Reduced Growth Factor Basement Membrane Extract (R&D Biosystems, 3533-010-02) and 50%
PBS. In mice injected with cells carrying a dox-inducible construct, water containing 0.5 mg/ml Dox (Sigma, D9891-25G) and 5%
sucrose (Sigma, S9378) was administered 3 times a week upon tumor formation and for a maximum of 3 months. Injection of
0.02 mg in PBS of recombinant mEphrin-B2-hFC chimera or ChromPure IgG hFC fragment was performed intra-peritoneal (i.p.)
and with a frequency of twice per week. Injection of 25mg/Kg Bevacizumab in PBS (Genentech, Avastin) or 26.25mg/Kg Paclitaxel
in PBS (Bristol-Myers Squibb, Taxol) or Ultra-LEAF purified human IgG1 Isotype control (Biolegend, 403502) was performed i.p.
and with a frequency of twice per week. Injection of 15 mg/Kg Paclitaxel in PBS (Bristol-Myers Squibb, Taxol) was performed
i.p. once a week. Bevacizumab and Paclitaxel were obtained from the Pharmacy of the University Hospital Basel, under permit
#RL0004-V07-B02.
Metastatic index and organ fixation
Mice bearing GFP/Luc or mCherry/Luc tumors were subcutaneously (s.c.) injected with 3 mg D-Firefly-Luciferin (Gold Bio, LUCK-
5G). After 10 minutes, bioluminescent images of the full mouse were taken at IVIS Lumina LT (Perkin Elmer). After euthanasia and
within 20 minutes from the injection of luciferin, primary tumor and metastatic organs were imaged separately. Metastatic index
was calculated as the ratio of the total flux in photons per second (Ph/s) of themetastatic organ over the primary tumor. Sample exclu-
sion is applied to metastatic index greater than 1.3, mostly due to imprecise measurement as a consequence to high primary tumor
necrosis. Primary tumors and metastatic organs were fixed in PFA-Lysine-Phosphate buffer (4% PFA, 0.2 M L-Lysine, 0.2% NaIO3
and 0.1 M Phosphate buffer, pH 7.4 – 0.2 M NaH2PO4 and 0.2 M H2HPO4) O/N at 4
C. Subsequently, organs were incubated in 30%
sucrose for 6 hours before O.C.T. embedding.
CTC capture and quantification
Patient-derived CTCs were enriched on the Parsortix Cell Separation Cassette (GEN3D6.5, ANGLE) within 1 hour of blood draw. In-
cassette staining was performed with the antibody cocktail for anti-human EpCAM-AF488 (Cell Signaling, CST5198), anti-human
HER2-AF488 (BioLegend, 324410) and anti-human EGFR-FITC (GeneTex, GTX11400). For mouse-derived CTCs capture, mice
were anaesthetized using isoflurane and blood was drawn from the central circulation through cardiac puncture or from the tumor
draining vessel. Blood was processed immediately on the Parsortix system for CTCs enrichment. For all xenograft models withe3 Cell Reports 32, 108105, September 8, 2020
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In-cassette staining for hypoxic statuswas performedwith HypoxiaRed (Enzo Life technologies, ENZ-51042-K500) in the presence of
1%BSA (Sigma, A8412) in PBS. For the HIF1a reporter/HypoxiaRed correlation analysis and the in vitro validation of the dye, LM2 or
BR16 cells were stained for the HypoxiaRed according to the manufacturer protocol. Quantification of mouse-derived CTCs with
HIF1a reporter or HypoxiaRed-stained CTCs was achieved by releasing the CTCs from the Parsortix system into a PBS solution
and by analyzing the cell suspension through ImageStreamX Mark II (Amnis, Luminex). In particular, all the events between 13-
100 mm diameter were analyzed with 40x objective and at slow flow rate for the acquisition of images. The 405, 488, 561 and side
scatter (SSC) lasers were used. GFP/Luc or eYFP were acquired on Channel 2 (532/56), mCherry/Luc and HypoxiaRed on channel
4 (628/69). Analysis was performed at the IDEAS software (Luminex, v6.0). Final graphs were created with FlowJo v10.
3D volumes and blood vessel functionality analysis
Mice bearing LM2, 4T1 or BR16 mCherry/Luc tumors expressing the HIF1a reporter were sacrificed at week 5, 3 or month 6 respec-
tively, immediately after intra-peritoneal (i.p.) injection of 1.2 mg of Pimonidazole (Hypoxyprobe, HP-500mg) and intra-venous (i.v.)
injection of 1 mg of Dextran-Biotin 70 kDa (Thermo Fisher, D1957), 1 hour and 15minutes before the experiment termination, respec-
tively. Tissue sections were prepared, stained, and imaged as previously described (Coutu et al., 2018). Primary tumors were fixed for
24 hours in 4% PFA at 4C. Derived tissues were embedded in 4% low-gelling temperature agarose (Sigma, A9414) and subse-
quently sectioned (50-100 mm thick sections) using the Leica VT1200 S vibratome. For the IF staining, all protocol steps were
performed at room temperature (RT) with permeabilization for a minimum of 2 hours followed by an O/N incubation with primary an-
tibodies against GFP (Novus Biologicals, NB600-308), Pimonidazole-Red549 (Hypoxyprobe, Red549-Mab), human pan-Cytokeratin
(7, 8, 18, 19) (Miltenyi Biotec, 130-112-743), and mouse CD31 (R&D, AF3628). Secondary antibodies against goat IgG-CF405 (Bio-
tium, 20416), goat IgG-AF488 (Thermo Fisher, A-11055), goat IgG-DyLight 549 (Abcam, ab96933), rabbit IgG-CF405 (Biotium,
20420), mouse IgG-AF647 (Thermo Fisher, A-31571), human IgG-AF488 (Jackson Immuno Research, 709-545-149), human IgG-
Cy3 (Jackson Immuno Research, 709-165-149), streptavidin-AF555 (Thermo Fisher, S32355), streptavidin-AF549 (Thermo Fisher,
S32356), streptavidin-AF405 (Thermo Fisher, AF446-SP) were incubated for 2 hours after extensive washings. 3D volumes were con-
structed using Imaris (Bitplane, v9). Surface rendering was created for all the channels individually (mCherry or hCK, Pimonidazole,
eYFP, CD31, Dextran). Area and volume of the individual surfaces were calculated with the Imaris ‘‘Measurement Pro’’ package.
Channels were masked for ‘‘voxels out equal to 0’’ for colocalizing voxels of the respective channels, and with ‘‘voxels in equal to
0’’ for non-colocalizing voxels of the channels. Surface rendering of the masked channels was constructed to further calculate
the area or volume of colocalizing channels.
Assessment of metastatic potential of hypoxic and normoxic CTC clusters
CTCs frommice bearing LM2-mCherry/Luc or BR16 tumors and expressing the HIF1a reporter were enriched with the Parsortix de-
vice, stained for mouse CD45-AF647 (Biolegend, 103124) and later released in a PBS solution, as described above. The CTC sus-
pension was thenmicromanipulated using CellCelector (ALS) and a 50 mmglass capillary was used to isolate CTC clusters from the
CTC suspension. The total number of cells (in clusters or single cell form) was counted and injected through the tail vein of NSG tu-
mor-free female recipients. BR16-mCherry/Luc cells, expressing the HIF1a reporter, were cultured in a humidified hypoxia chamber
at 0.1%O2 for four days before sorting. A control dishwas cultured in a humidified incubator at 20%O2 for four days before sorting. At
day four, cells were collected and sorted at the BD Influx sorter at five pounds per square inch (psi) and with a 200 mm nozzle to pre-
serve the integrity of both single and clustered cells. Equal numbers of eYFP-positive or eYFP-negative cells (in a cluster form) were
injected through the tail vein of NSG tumor-free female recipients. I.v. injected mice were monitored weekly through non-invasive
bioluminescence imaging and sacrificed when showing signs of distress.
CTC isolation and RNA Sequencing
Single cells or CTC clusters were isolated using CellCelector based on the color combination of interest and deposited into indi-
vidual tubes (Corning Axygen, PCR-02-L-C) containing 2.5 mL RLT Plus lysis buffer (QIAGEN, 1053393) and 1U/ml SUPERase In
RNase Inhibitor (Invitrogen, AM2694) (Donato et al., 2019). Samples were immediately frozen on dry ice and kept at 80C until
further processing. Following previously published protocol for parallel DNA and RNA sequencing from individual cells (Macaulay
et al., 2015), transcriptomes of lysed cells were separated and amplified according to the Smart-Seq2 (Picelli et al., 2013). Subse-
quently, libraries were prepared with Nextera XT (Illumina) and sequenced on NextSeq75 single read for RNA.
Mass spectrometry using tandem mass tags
Primary tumors frommice bearing LM2-mCherry/Luc tumors and expressing the HIF1a reporter weremanually dissociated, digested
with 0.1 mg/ml of Collagenase Type IV (Sigma Aldrich, C5138-1G) and 0.5 mg/ml DNase I (Roche, 11284932001) for 30’ at 37C, and
purified using the Dead cell removal kit (Miltenyi Biotec, 130-090-101). mCherry/Luc positive cells were sorted based on the expres-
sion of the HIF1a reporter and classified as hypoxic (eYFP-positive) or normoxic (eYFP-negative). One million sorted cells were
pelleted, washed twice with PBS and snap-frozen. CTCs frommice bearing LM2-mCherry/Luc tumors and expressing the HIF1a re-
porter were enriched, stained with anti-human CD298 PE (Biolegend, 341704) and anti-mouse CD45 AF647 and sorted in single
CTCs and CTC clusters based on the expression of the HIF1a reporter and classified as hypoxic (eYFP-positive) or normoxicCell Reports 32, 108105, September 8, 2020 e4
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OPEN ACCESS(eYFP-negative). Sorted cells were pelleted, washed twice with PBS and snap-frozen. Cells were lysed in 8M Urea (Sigma), 0.1M
ammonium bicarbonate in presence of phosphatase inhibitors (Sigma, P5726 and P0044) using strong ultra-sonication (Bioruptor,
10 cycles, 30 s on/off, Diagenode, Belgium). Proteins were reduced with 5 mM TCEP for 60 min at 37C and alkylated with
10 mM chloroacetamide for 30 min at 37C. Urea was diluted with 100 mM ammonium bicarbonate to the final concentration of
1.6M and proteins were digested by with sequencing-grade modified trypsin (1/50, w/w; Promega, Madison, Wisconsin) overnight
at 37C. Samples were then acidified with 5% TFA and peptides were desalted on C18 reversed-phase spin columns according to
the manufacturer’s instructions (Macrospin, Harvard Apparatus). 25 mg of peptides were labeled with tandem mass isobaric tags
(TMT 10-plex, Thermo Fisher Scientific) according to the manufacturer’s instructions. To control for ratio distortion, a peptide cali-
bration mixture consisting of six standard peptide mix were added to each sample prior TMT labeling. After labeling, TMT peptides
were pooled and again desalted on C18 reversed-phase spin columns. TMT-labeled peptides were fractionated by high-pH reversed
phase separation using a XBridge Peptide BEHC18 column (3,5 mm, 130 A, 1mm x 150mm,Waters) on an Agilent 1260 Infinity HPLC
system. Peptides were loaded on a column in ammonium formate (20mM, pH 10) in water and eluted using a two-step linear gradient
starting from 2% to 10% in 5 minutes and then to 50% (v/v) 90% acetonitrile / 10% ammonium formate (20 mM, pH 10) over 55 mi-
nutes at a flow rate of 42 ml/min. In total 36 fractions were collected and pooled into 12 fractions. 1 mg of peptides were processed for
LC-MS. Chromatographic separation of peptides was carried out using an EASY nano-LC 1000 system (Thermo Fisher Scientific),
equipped with a heated RP-HPLC column (75 mm x 37 cm) packed in-house with 1.9 mm C18 resin (Reprosil-AQ Pur, Dr. Maisch).
Peptides were separated using a stepwise gradient ranging from 95% solvent A (0.15% formic acid, 2% acetonitrile) and 5% solvent
B (80% acetonitrile, 20% water, 0.15% formic acid) to 45% solvent B over 120 minutes at a flow rate of 200 nl/min. Mass spectrom-
etry analysis was performed on QExactive mass spectrometer equipped with a nano-electrospray ion source (both Thermo Fisher
Scientific). Each MS1 scan was followed by high-collision-dissociation (HCD) of the 10 most abundant precursor ions with dynamic
exclusion for 30 s. For MS1, 3e6 ions were accumulated in the Orbitrap cell and scanned at a resolution of 120,000 FWHM (at 200 m/
z). MS2 scans were acquired at a target setting of 1e5 ions, accumulation time of 100ms and a resolution of 30,000 FWHM (at 200m/
z). The normalized collision energywas set to 35%, themass isolationwindowwas set to 1.1m/z and onemicroscanwas acquired for
each spectrum.
Immunofluorescent staining of blood vessels and hypoxic cells
7 mm-thick frozen slices were blocked for 30 minutes in 0.1% Gelatin buffer (Sigma, G9391) for LM2 and 4T1, or 10% Donkey serum
buffer (Millipore, S30) for BR16. Primary antibodies for mouse CD31 (R&D, AF3628), Pimonidazole (Hypoxyprobe, Red549-Mab,
FITC-Mab, Pacific Blue-Mab), and human pan-Cytokeratin (i.e., cytokeratins 7, 8, 18, 19) (Miltenyi Biotec, 130-112-743) were incu-
bated O/N at 4C. Secondary antibodies against rabbit IgG-AF647 (Invitrogen, A31573), FITC IgG-CF633 (Scientific Laboratory sup-
ply, SAB 4600145), and goat IgG-AF633 (Thermo Fischer, A-21082) were incubated, after washing in PBS, for 1 hour at RT. Slides
were mounted with Vectashield Hard set with Dapi (Vectashield, VC-H-1400-L010). Slides were scanned at the Zeiss Axio Imager Z2
with a 20x dry objective. CD31 quantification was performed with Fiji (v2) using the plugin ‘‘color pixel counter’’ of the CD31 over the
total tumor background color area (e.g., mCherry or GFP). Pimonidazole quantification was performed with Fiji using the ‘‘colocal-
ization threshold’’ analysis tool of the total tumor background color over the pimonidazole.
Pimonidazole or Ki67 (Abcam, ab15580) staining on sorted CTCs was performed using Cytospin (500 rpm, 3 minutes), immediate
fixation in 4%PFA for 12minutes and staining as described above. Slides were imaged at Leica SP5 confocal microscope with a 40x
oil objective.
NDRG1 immunofluorescence and western blot analysis
O.C.T.-embedded consecutive sections of LM2-mCherry/Luc tumors expressing the HIF1a reporter were stained NDRG1 (Cell
Signaling, 9485). NDRG1 expression in hypoxic conditions was assessed by incubating LM2-mCherry/Luc cells in the presence
of 500 mMDFO or in hypoxia 0.1%O2 for 15 hours before lysis. Anti-NDRG1 (Cell signaling, 9395) was used to detect NDRG1 protein
and anti-alpha Tubulin (Sigma Aldrich, T9026) was used as loading control. LM2 cells were stably transduced with Dox-inducible
shRNAs targeting ORF of human NDRG1 (50- GAAAGAATCAAGGAGG - 30, 50 - GGAAAGAATCAAGGAGG - 30) (Dharmacon,
SMART).
QUANTIFICATION AND STATISTICAL ANALYSIS
Single-cell RNA-seq data processing
Quality assessment of RNA-seq data was performed using FastQC (v0.11.4) (https://www.bioinformatics.babraham.ac.uk/projects/
fastqc), FastQ Screen (v0.11.4) (https://www.bioinformatics.babraham.ac.uk/projects/fastq_screen), Kraken (v1.1) and visualized
with MultiQC (v0.8). Reads were quality trimmed with Trim Galore! (v0.4.2, https://www.bioinformatics.babraham.ac.uk/projects/
trim_galore/). Trimmed reads derived from xenograft models were aligned to human (GRCh38) andmouse (GRCm38) genomes using
STAR (v2.5.2a) and assigned to either the human or mouse using disambiguate (v 1.0.0). Transcript-level expression of transcripts
obtained from Ensembl release 89 was quantified using Salmon (v0.11.3, parameters–seqBias and–gcBias). Gene-level expression
was obtained by aggregating transcript-level abundances using tximport. Quality control of processed data was performed with the
scater package. Samples with at least 500’000 counts from endogenous genes, 8’000 features detected (thresholdR 1 count) ande5 Cell Reports 32, 108105, September 8, 2020
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each sample using Seurat.
Differential expression
Differential expression (DE) between normoxic and hypoxic CTC clusters was computed with the likelihood ratio test method in the
edgeR package (v3.20.1) and using the rounded length-scaled TPM as input. Genes detected in less than 25% of the samples
(threshold 1 TPM) were removed prior to the DE analysis. To define hypoxia, we used a combined criterion defined by HypoxiaRed
staining and hypoxia scoring based on gene expression. Hypoxia score was generated independently in each model (NSG-LM2,
NSG-BR16 and BR61) by ranking samples according to their mean expression of VEGFA and HIF1A transcripts and calculating
the fractional rank normalized between 0 and 1. Scores above the median were considered as positive. Hypoxic CTC clusters
(n = 14) were defined as positive for both hypoxia score and HypoxiaRed. On the contrary, normoxic CTC clusters (n = 17) were
defined as negative for both hypoxia score and HypoxiaRed. Samples with discordant results for both criteria were not considered
for DE analysis.
Validation of the Hypoxic CTC cluster gene signature
The validation our hypoxia signature was performed using the dataset GSE109761 (Szczerba et al., 2019) from NCBI Gene Expres-
sion Omnibus (GEO). The dataset contains 62 single CTCs and 21 CTC clusters from a total of 13 breast cancer patients. Counts per
million reads (CPM) were calculated after normalization using the size factors included in the SingleCellExperiment object. The
expression matrix was standardized at gene-level (z-scores) using log2 (CPM+1) values as input. Hypoxia score was assigned to
each sample by averaging the z-scores across the 25 genes upregulated in the signature. Bootstrapping approach was performed
to account for higher dropout rate in single CTC compared CTC clusters. For this, an expression score was computed for 10’000
random sets of 25 genes in the same fashion as for hypoxia score, and the empirical distribution of the one-sided Student t-statistic
comparing single CTC and CTC clusters was calculated. The bootstrapped P value obtained was 0.047.
Overall survival analysis using TCGA data
Harmonized gene expression quantification data of Breast Invasive Carcinoma Stage I samples of the Cancer Genome Atlas (TCGA-
BRCA) was downloaded from the Genomic Data Commons Data Portal (GDC) using the TCGAbiolinks package. The expression ma-
trix was constructed using the Fragments Per Kilobase of transcript per Million mapped reads normalized using upper quartile
(FPKM-UQ) for each sample as obtained with the HTSeq workflow. Clinical data were obtained from the TCGA Pan-Cancer Clinical
Data Resource (TCGA-CDR) and overall survival was defined as death from any cause. Hypoxia score (HS) on TCGA-BRCA data was
constructed by calculating the mean of the gene-level standardized expression (z-scores) across the 25 genes found upregulated in
hypoxic CTC clusters and the signatures developed by Buffa et al. (2010), Winter et al. (2007), Ragnum et al. (2015) and Elvidge et al.
(2006). HS was then divided by quantiles and the overall survival of patients from Q1 and Q4 was compared using the Kaplan-Meier
method using the survival package. The significance between both groups was assessed using the log-rank test. Time-dependent
receiver operator curves (ROC) using a predictive time of 10 years were computed using the Nearest Neighbor Estimation (NNE)
method implemented in the survivalROC package.
Distant metastasis-free survival
Distant metastasis-free survival analysis was performed onmultiple microarray breast cancer studies from GEO using the online tool
KM-plotter (https://kmplot.com/analysis/index.php?p=service&cancer=breast; accessed 31 October 2019). The mean expression
across the optimal probes for the 25 genes found upregulated in hypoxic CTC clusters was used to divide samples into quartiles.
A total of 664 patients were selected for the analysis with a maximum follow-up period of 10 years.
TMT-MS analysis
The acquired raw-files were converted to the mgf format and searched using the MASCOT algorithm (Matrix Science, Version 2.4.1).
The mgf files were searched against database containing normal and reverse sequences of the of Uniprot entries Homo sapiens
(2019/03/07), the six calibration mix proteins and commonly observed contaminants (in total 41,592 sequences for Homo sapiens).
The MS1 ion tolerance was set to 10 ppm and fragment ion tolerance was set to 0.02 Da. The search criteria were set as follows: full
tryptic specificity was required, 3 missed cleavages were allowed, carbamidomethylation (C), TMT6plex (K and peptide n-terminus)
were set as fixed modification and oxidation (M) as a variable modification. Next, the database search results were imported to the
Scaffold Q+ software (version 4.3.2, Proteome Software Inc., Portland, OR) and the protein FDR rate was set to 1%. Acquired re-
porter ion intensities in the experiments were employed for automated quantification and statics analysis using modified SafeQuant
R script (v2.3). A q value < 0.1 was used as cutoff of significance. All the significant proteins were filtered for a unique entry name and
run for gene ontology analysis using gProfiler web server and gProfileR package v 0.6.7.Cell Reports 32, 108105, September 8, 2020 e6
